The bill
Patients Deserve Price Tags Act
S. 2355, 119th Congress — read as touching Hospitals & Health Systems.
Sponsored by
Sen. Marshall, Roger [R-KS]
ID: M001198
Follow the money
The bill
S. 2355, 119th Congress — read as touching Hospitals & Health Systems.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
24 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
This bill's text tracks the "Department of Health and Human Services" section, p. 533-535 of the Mandate for Leadership.
Track this bill's progress through the legislative process
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 522.
July 26, 2026
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
**Summary of S. 2355: Patients Deserve Price Tags Act**
**1. Main Purpose & Objectives** The Patients Deserve Price Tags Act aims to mandate comprehensive price transparency for hospitals and health insurers by amending the Public Health Service Act. Its stated goal is to empower patients with clear, accessible pricing information so they can make informed healthcare decisions and avoid surprise bills. In reality, it’s a performative gesture dressed up as patient empowerment—another attempt to fix a broken system with disclosure theater while ignoring the root causes of exorbitant healthcare prices: monopolistic provider consolidation, opaque payer negotiations, and a fee-for-service model that rewards volume over value. The bill pretends that if patients just had a spreadsheet, they’d somehow negotiate like savvy consumers in a market that doesn’t function like one.
**2. Key Provisions & Changes to Existing Law** The bill strengthens existing hospital price transparency rules under Section 2718 of the Public Health Service Act (originally from the ACA). It requires hospitals to: - Publish **standard charges** monthly, free and without subscription, in both machine-readable and consumer-friendly formats. - Disclose **gross charges**, **discounted cash prices**, and **payer-specific negotiated rates** for all items and services, including billing codes (CPT, HCPCS, DRG, NDC). - Provide a **plain-language explanation** of charity care policies linked to price disclosures. - Expand the list of "shoppable services" to eventually include **all** such services (building toward a 300-service minimum by 2026, then full inclusion). - Mandate disclosure of **negotiation algorithms or formulas** if rates are not flat fees. - Extend similar transparency requirements to **health insurers**, requiring them to disclose negotiated rates with providers and out-of-network allowed amounts. The bill also enhances enforcement by empowering HHS to impose civil monetary penalties for noncompliance—though historically, such penalties have been rare and weakly enforced.
**3. Affected Parties & Stakeholders** - **Hospitals & Health Systems**: Forced to reveal pricing secrets they’ve long guarded as competitive leverage. Expect lobbying, loophole exploitation, and creative noncompliance (e.g., burying data in unusable formats). - **Insurers**: Must expose their negotiated rates—information they treat as trade secrets. This threatens their ability to steer patients and maintain profit margins via opaque contracts. - **Patients**: Theoretically gain tools to compare prices, but in practice, most lack the time, health literacy, or leverage to act on this data—especially during emergencies or when facing limited provider choice. - **Employers & Self-Insured Plans**: Could benefit from better data to negotiate with providers and insurers, potentially reducing costs. - **HHS & State Agencies**: Gain expanded oversight duties—though without significant funding increases, enforcement will likely remain lax. - **Lobbyists & Consultants**: The real winners. Expect a boom in "transparency compliance" firms selling software and advisory services to hospitals gaming the system.
**4. Potential Impact & Implications** If fully implemented and enforced, this bill could marginally increase price competition in non-emergency, shoppable services (e.g., MRIs, colonoscopies). But healthcare isn’t a retail market: prices are driven by consolidation, not consumer choice. Most spending occurs in emergencies, chronic care, or inpatient settings where patients can’t shop. The bill’s deeper implication is ideological: it reinforces the myth that healthcare consumers can "shop smart" their way to affordability, deflecting blame from systemic failures. It’s a placebo for public frustration—making politicians look active while avoiding hard choices like price caps, public options, or antitrust enforcement. In short: **Patients Deserve Price Tags Act** is less about empowering patients and more about giving Congress a transparent-looking bandage for a hemorrhaging system—one that treats the symptom of confusion while ignoring the disease of profiteering. Expect minimal real impact, maximal paperwork, and another round of congressional self-congratulation for doing almost nothing.
Sen. Marshall, Roger [R-KS]
Congress 119 • 2024 Election Cycle
No organization contributions found
No committee contributions found
This bill has 10 cosponsors. Below are their top campaign contributors.
ID: H000273
Top Contributors
23
ID: G000386
Top Contributors
23
ID: H001076
Top Contributors
20
ID: S001232
Top Contributors
100
ID: E000295
Top Contributors
23
ID: B001230
Top Contributors
72
ID: M001242
Top Contributors
32
ID: S001217
Top Contributors
22
ID: K000394
Top Contributors
29
ID: H001104
Top Contributors
0
No contribution data available
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 31 nodes and 38 connections
Total contributions: $38
Showing top 19 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 2 helped, 3 harmed.
Section 2(e)(5)(B)(i) imposes civil monetary penalties on hospitals for noncompliance with price transparency requirements, with penalties scaling by bed count (e.g., $300/day for ≤30 beds, $12.50/bed/day for 30-100 beds, etc.). This creates a direct financial cost for hospitals that fail to comply.
Section 2(e)(1)(B)(i) requires hospitals to disclose standard charges including National Drug Code identifiers for drugs, increasing transparency that benefits pharmaceutical manufacturers by enabling price comparison and potentially driving competition; Section 3(f)(2)(A) similarly requires clinical labs to disclose NDC codes for drugs in tests, further aiding pharmaceutical price transparency.
Section 6(b)(E)(H)(iii) subjects health plans that fail to comply with rate and payment information disclosure requirements to civil monetary penalties of up to $300 per member per day or $10,000,000 (whichever is lesser), imposing significant costs on insurers for noncompliance.
Section 2(e)(1)(B)(i) includes National Drug Code and other identifiers that apply to biologics and gene therapies; Section 3(f)(2)(A) extends this to clinical diagnostic lab tests, which often involve biotech-developed assays, thereby increasing transparency for biotech products and potentially aiding market adoption.
Section 3(f) and Section 4(g) extend price transparency requirements to clinical diagnostic laboratories and imaging service providers, which often include medical device manufacturers that furnish diagnostic tests and imaging services. These entities face civil penalties (up to $300/day for labs, $300/day for imaging providers) for noncompliance, creating compliance costs.
This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.
AI Analysis:
"The Patients Deserve Price Tags Act directly implements hospital price transparency measures that Project 2025 endorses through its support for the Transparency in Coverage rule and surprise medical bills reform, showing strong thematic overlap."
— 500 — Mandate for Leadership: The Conservative Promise 32. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 33. Brian Blase, “Managed Care in Medicaid: Need for Oversight, Accountability, and Reform,” Paragon Health Institute Policy Brief, October 13, 2022, https://paragoninstitute.org/wp-content/uploads/2022/10/20221012- Managed-Care-in-Medicaid-Need-for-Oversight-Accountability-and-Reform-FOR-DISTRIBUTION-V2.pdf (accessed February 13, 2023). 34. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 35. 42 U.S. Code § 1315, https://www.law.cornell.edu/uscode/text/42/1315 (accessed March 17, 2023). 36. Chad D. Savage and Lee S. Gross, “Direct Primary Care: Update and Road Map for Patient-Centered Reforms,” Heritage Foundation Backgrounder No. 3635, June 28, 2021, https://www.heritage.org/sites/default/ files/2021-06/BG3635.pdf. 37. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No. 116-260, 116th Congress, December 27, 2020, Division BB, Title I, https://www.congress.gov/116/plaws/publ260/PLAW-116publ260.pdf (accessed March 17, 2023). 38. Doug Badger, “On Surprise Medical Bills, Congress Should Side with Consumers, Not Special Interests,” Heritage Foundation Commentary, January 31, 2020, https://www.heritage.org/health-care-reform/ commentary/surprise-medical-bills-congress-should-side-consumers-not-special. 39. Edmund F. Haislmaier and Abigail Slagle, “Premiums, Choices, Deductibles, Care Access, and Government Dependence Under the Affordable Care Act: 2021 State-by-State Review,” Heritage Foundation Backgrounder No. 3668, November 2, 2021, https://www.heritage.org/sites/default/files/2021-11/BG3668.pdf. 40. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, “Transparency in Coverage,” Final Rule, Federal Register, Vol. 85, No. 219 (November 12, 2020), pp. 72158–72310, https://www.govinfo.gov/ content/pkg/FR-2020-11-12/pdf/2020-24591.pdf (accessed March 17, 2023). 41. David N. Bernstein and Robert E. Moffit, “New Price Transparency Rule Will Help Transform America’s Health Care System,” Heritage Foundation Commentary, November 1, 2020, https://www.heritage.org/health-care- reform/commentary/new-price-transparency-rule-will-help-transform-americas-health-care. 42. Sluzala and Haislmaier, “Lessons from COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing.” 43. Ibid. 44. Most recently enacted in H.R. 2471, Consolidated Appropriations Act, 2022, Public Law No. 117-103, 117th Congress, March 15, 2022, Division H, Title V, §§ 506–507, https://www.congress.gov/117/plaws/publ103/ PLAW-117publ103.pdf (accessed March 17, 2023). 45. President Joseph R. Biden Jr., Executive Order 14079, “Securing Access to Reproductive and Other Healthcare Services,” August 3, 2022, in Federal Register, Vol. 87, No. 154 (August 11, 2022), pp. 49505–49507, https:// www.govinfo.gov/content/pkg/FR-2022-08-11/pdf/2022-17420.pdf (accessed March 16, 2023). 46. Planned Parenthood, 2020–2021 Annual Report, p. 27, https://www.plannedparenthood.org/uploads/ filer_public/40/8f/408fc2ad-c8c2-48da-ad87-be5cc257d370/211214-ppfa-annualreport-20-21-c3-digital.pdf (accessed March 22, 2023). 47. Ibid., pp. 30 and 31. Total revenue of $1,714.4 million (p. 30) minus $1,580.7 million in total expenses (p. 31) yields $133,7 million. 48. Ibid., p. 28. 49. Ibid., p. 30. 50. H.R. 372, Protecting Life and Taxpayers Act of 2023, 118th Congress, introduced January 17, 2023, https://www. congress.gov/118/bills/hr372/BILLS-118hr372ih.pdf (accessed March 17, 2023). 51. 42 U.S. Code § 18023, https://www.law.cornell.edu/uscode/text/42/18023 (accessed March 17, 2023). 52. H.R. 3128, Consolidated Omnibus Budget Reconciliation Act of 1985, Public Law No. 99-272, 99th Congress, April 7, 1986, Title IX, Subtitle A, Part 1, Subpart B, § 9121, https://www.congress.gov/99/statute/STATUTE-100/ STATUTE-100-Pg82.pdf (accessed March 17, 2023). 53. H.R. 8070, Rehabilitation Act of 1973, Public Law No. 93-112, 93rd Congress, September 26, 1973, https://www. congress.gov/93/statute/STATUTE-87/STATUTE-87-Pg355.pdf (accessed March 17, 2023).
AI Analysis:
"The Patients Deserve Price Tags Act aligns with Project 2025's emphasis on price transparency in healthcare, particularly the call to codify price transparency regulations under Legacy Medicare Reform. Both seek to increase transparency in healthcare pricing to empower consumers and promote competition."
— 464 — Mandate for Leadership: The Conservative Promise l The Risk Adjustment Data Validation (RADV) rule; l The Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) demonstration; and l The Global and Professional Direct Contracting (GPDC, rebranded as the Accountable Care Organization Realizing Equity, Access, and Community Health or ACO REACH) model. Additionally, regulations should advance site neutrality by eliminating the inpa- tient-only list and expanding the ambulatory surgical center covered procedures list. Medicare generally pays more for inpatient hospital procedures and less for the same procedures performed in an outpatient setting. Whether a medical ser- vice is delivered in a physician’s office, a clinic, or a hospital setting, the Medicare payment for that service should be the same. CMS should expand the application of site-neutral payment options to more settings. Such a policy would level the playing field among providers and remove the financial disabilities for medical professionals who would compete with hospital systems.23 Finally, HHS needs to restore and enhance conscience protection regulations that allow medical practitioners to participate in federal health care programs without being compelled to provide sex changes or similar services. LEGISLATIVE PROPOSALS l Remove restrictions on physician-owned hospitals. The Affordable Care Act (ACA)24 imposed restrictions prohibiting Medicare from reimbursing physician-owned and specialty hospitals. The current restrictions do little more than serve the special interests of large hospital systems and undercut consumer choice of high-quality, specialty care. These restrictions should be removed so that physician-owned hospitals can compete with other hospitals in serving Medicare patients.25 l Encourage more direct competition between Medicare Advantage and private plans. Medicare Advantage (MA), a system of competing private health plans, is the major alternative to traditional Medicare for America’s large and growing cohort of seniors. The program provides beneficiaries with a wide range of competitive health plan choices—a richer set of benefits than traditional Medicare provides and at a reasonable cost. Equally as important, the MA program has been registering consistently high marks for superior performance in delivering high-quality care. Critical reforms are still needed to strengthen and improve the program for the future. Specifically: — 465 — Department of Health and Human Services 1. Make Medicare Advantage the default enrollment option. 2. Give beneficiaries direct control of how they spend Medicare dollars. 3. Remove burdensome policies that micromanage MA plans. 4. Replace the complex formula-based payment model with a competitive bidding model. 5. Reconfigure the current risk adjustment model. 6. Remove restrictions on key benefits and services, including those related to prescription drugs, hospice care, and medical savings account plans.26 Legacy Medicare Reform. Legislation reforming legacy (non-MA) Medicare should: l Base payments on the health status of the patient or intensity of the service rather than where the patient happens to receive that service. l Replace the bureaucrat-driven fee-for-service system with value- based payments to empower patients to find the care that best serves their needs. l Codify price transparency regulations. l Restructure 340B drug subsidies27 toward beneficiaries rather than hospitals. l Repeal harmful health policies enacted under the Obama and Biden Administrations such as the Medicare Shared Savings Program28 and Inflation Reduction Act.29 Medicare Part D Reform. The Inflation Reduction Act (IRA) created a drug price negotiation program in Medicare that replaced the existing private-sector negotiations in Part D with government price controls for prescription drugs. These government price controls will limit access to medications and reduce patient access to new medication. This “negotiation” program should be repealed, and reforms in Part D that will have meaningful impact for seniors should be pursued. Other reforms should include eliminating the coverage gap in Part D, reducing the government share in
AI Analysis:
"The Patients Deserve Price Tags Act aligns with Project 2025's emphasis on price transparency in healthcare, particularly the call to 'codify price transparency regulations' under Legacy Medicare Reform. While the bill focuses on hospital pricing transparency for all patients—not specifically Medicare beneficiaries—it shares the broader goal of increasing transparency to empower patients and drive competition."
— 465 — Department of Health and Human Services 1. Make Medicare Advantage the default enrollment option. 2. Give beneficiaries direct control of how they spend Medicare dollars. 3. Remove burdensome policies that micromanage MA plans. 4. Replace the complex formula-based payment model with a competitive bidding model. 5. Reconfigure the current risk adjustment model. 6. Remove restrictions on key benefits and services, including those related to prescription drugs, hospice care, and medical savings account plans.26 Legacy Medicare Reform. Legislation reforming legacy (non-MA) Medicare should: l Base payments on the health status of the patient or intensity of the service rather than where the patient happens to receive that service. l Replace the bureaucrat-driven fee-for-service system with value- based payments to empower patients to find the care that best serves their needs. l Codify price transparency regulations. l Restructure 340B drug subsidies27 toward beneficiaries rather than hospitals. l Repeal harmful health policies enacted under the Obama and Biden Administrations such as the Medicare Shared Savings Program28 and Inflation Reduction Act.29 Medicare Part D Reform. The Inflation Reduction Act (IRA) created a drug price negotiation program in Medicare that replaced the existing private-sector negotiations in Part D with government price controls for prescription drugs. These government price controls will limit access to medications and reduce patient access to new medication. This “negotiation” program should be repealed, and reforms in Part D that will have meaningful impact for seniors should be pursued. Other reforms should include eliminating the coverage gap in Part D, reducing the government share in — 466 — Mandate for Leadership: The Conservative Promise the catastrophic tier, and requiring manufacturers to bear a larger share. Until the IRA is repealed, an Administration that is required to implement it must do so in a way that is prudent with its authority, minimizing the harmful effects of the law’s policies and avoiding even worse unintended consequences.30 Medicaid. Over the past 45 years, Medicaid and the health safety net have evolved into a cumbersome, complicated, and unaffordable burden on nearly every state. The program is failing some of the most vulnerable patients; is a prime target for waste, fraud, and abuse; and is consuming more of state and federal budgets. The dramatic increase in Medicaid expenditures is due in large part to the ACA (Obamacare), which mandates that states must expand their Medicaid eligibility standards to include all individuals at or below 138 percent of the federal poverty level (FPL), and the public health emergency, which has prohibited states from performing basic eligibility reviews. The overlap of available benefits among the various health agencies has led to a complex, confusing system that is nearly impossible to navigate—even for recipients. Recipients are often faced with a “welfare cliff” of benefit losses as they earn above a certain amount, which is contrary to the fundamental purpose of empowering individuals to achieve economic independence. Benefits increasingly involve nonmedical services such as air conditioning and housing, many of which are already handled by departments other than HHS. Improper payments within Medicaid are higher than those of any other federal program. These payments are evidence of the inappropriateness of Medicaid’s expansion, which, stemming largely from public health emergency maintenance of effort (MOE) requirements and the Affordable Care Act, has crowded out the primary targets of these programs: those who are most in need. True health care reform cannot be accomplished in a bureaucratic silo or only through Medicaid and health safety net programs. Reform of the tax code is also essential to genuine, effective reform of our health care system. All components of the health care system should be part of the reform efforts, and it is imperative that the system be modified to assist states with their current programs. Therefore, the next Administration should: l Reform financing. Allow states to have a more flexible, accountable, predictable, transparent, and efficient financing mechanism to deliver medical services. This system should include a more balanced or blended match rate, block grants, aggregate caps, or per capita caps. Any financial system should be designed to encourage and incentivize innovation and the efficient delivery of health care services. Federal and state financial participation in the Medicaid program should be rational, predictable, and reasonable. It should also incentivize states to save money and improve the quality of health care.
Showing 3 of 5 policy matches
Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.